Absci (ABSI) Net Cash Flow (2020 - 2026)
Absci (ABSI) posted Net Cash Flow of -$11.4 million for Q1 2026, down 96.6% sequentially from -$5.8 million in Q4 2025, and down 292.67% YoY from $5.9 million in Q1 2025.
Absci (ABSI) Net Cash Flow (2020 - 2026) Analysis & Trends
Absci has reported Net Cash Flow for 7 years, with the latest figure at -$11.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 292.67% year-over-year to -$11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.4 million (down 346.86% YoY) and the FY2025 annual result came in at -$37.1 million, down 18.07% from the prior year.
- Net Cash Flow slipped to -$11.4 million in Q1 2026 per ABSI's latest filing, from -$5.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $49.7 million in Q2 2023 and troughed at -$98.7 million in Q3 2022.
- A 5-year average of -$15.9 million and a median of -$11.4 million in 2026 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow surged 277.63% in 2023, then plunged 422.74% in 2025.
- Over 5 years, Net Cash Flow stood at -$47.4 million in 2022, then soared by 105.92% to $2.8 million in 2023, then grew by 9.43% to $3.1 million in 2024, then tumbled by 289.0% to -$5.8 million in 2025, then sank by 96.6% to -$11.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$11.4 million, -$5.8 million, and -$28.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 99.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.23 Mn |
| Jun 30, 2026 | 99.23 Mn |
| Mar 31, 2026 | -11.39 Mn |
| Mar 31, 2026 | -11.39 Mn |
| Dec 31, 2025 | -5.79 Mn |
| Dec 31, 2025 | -5.79 Mn |
| Sep 30, 2025 | -28.42 Mn |
| Sep 30, 2025 | -28.42 Mn |
| Jun 30, 2025 | -8.84 Mn |
| Jun 30, 2025 | -8.84 Mn |
| Mar 31, 2025 | 5.91 Mn |
| Mar 31, 2025 | 5.91 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | -5.44 Mn |
| Sep 30, 2024 | -5.44 Mn |
| Jun 30, 2024 | -15.72 Mn |
| Jun 30, 2024 | -15.72 Mn |
| Mar 31, 2024 | -13.36 Mn |
| Mar 31, 2024 | -13.36 Mn |